Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Bide Pharmatech Co., Ltd. (688073.SS)

Compare
41.00
-0.16
(-0.39%)
At close: 3:00:03 PM GMT+8
Loading Chart for 688073.SS
  • Previous Close 41.16
  • Open 41.71
  • Bid 41.00 x --
  • Ask 41.04 x --
  • Day's Range 40.52 - 41.95
  • 52 Week Range 28.50 - 61.66
  • Volume 1,555,981
  • Avg. Volume 1,333,272
  • Market Cap (intraday) 3.726B
  • Beta (5Y Monthly) 0.52
  • PE Ratio (TTM) 45.56
  • EPS (TTM) 0.90
  • Earnings Date --
  • Forward Dividend & Yield 0.90 (2.19%)
  • Ex-Dividend Date Jun 26, 2024
  • 1y Target Est --

Bide Pharmatech Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company's products are used in life sciences, organic chemistry, materials science, analytical chemistry, and other applications. The company was incorporated in 2007 and is headquartered in Shanghai, China.

www.bidepharmatech.com

846

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 688073.SS

View More

Performance Overview: 688073.SS

Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

688073.SS
16.60%
SSE Composite Index (000001.SS)
2.65%

1-Year Return

688073.SS
21.55%
SSE Composite Index (000001.SS)
8.06%

3-Year Return

688073.SS
20.52%
SSE Composite Index (000001.SS)
1.15%

5-Year Return

688073.SS
20.52%
SSE Composite Index (000001.SS)
15.40%

Compare To: 688073.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 688073.SS

View More

Valuation Measures

Annual
As of 4/11/2025
  • Market Cap

    3.74B

  • Enterprise Value

    2.67B

  • Trailing P/E

    45.73

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.35

  • Price/Book (mrq)

    1.87

  • Enterprise Value/Revenue

    2.43

  • Enterprise Value/EBITDA

    26.30

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    7.29%

  • Return on Assets (ttm)

    2.42%

  • Return on Equity (ttm)

    3.90%

  • Revenue (ttm)

    1.1B

  • Net Income Avi to Common (ttm)

    80.03M

  • Diluted EPS (ttm)

    0.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.17B

  • Total Debt/Equity (mrq)

    4.47%

  • Levered Free Cash Flow (ttm)

    -7.25M

Research Analysis: 688073.SS

View More

Company Insights: 688073.SS

Research Reports: 688073.SS

View More